

amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist is administered subcutaneously.

29. A method according to claim 38 wherein said mammal is a human.

40. A method according to claim 39 wherein said insulin and said glucagon-like peptide 1 (7-36) amide agonist are administered to the human at a selected time prior to ingestion of a meal.

~~41. A method according to any of claims 38-40 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36).~~

42. A method according to any of claims 38-40 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36) amide.

~~43. A method of treating Type I diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist is administered subcutaneously.~~

44. A method according to claim 43 wherein said mammal is a human.

45. A method according to claim 44 wherein said glucagon-like peptide 1 (7-36) amide agonist is administered to the human at a selected time prior to ingestion of a meal.

46. A method according to any of claims 43-45 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36).

47. A method according to any of claims 43-45 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36) amide.

REMARKS

Claims 15-37 are currently pending in the application. Claims 15-19, 23-29 and 31-37 stand rejected. Dependent claims 20-22 and 28-30 have been held to define allowable subject matter but stand objected to because they depend from rejected claims.

By this response, Applicant has canceled rejected claims 15-19, 23-29 and 31-37 without prejudice to their inclusion in a continuing case. For the convenience of the Patent and Trademark Office, objected to dependent claims 20-22 and 28-30 have also been canceled and rewritten as new claims 38-47 so as not to depend on any rejected claim. No new matter has been added. All new claims 38-47 find support in the original